Pimozide-d4

Pimozide-d4 is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].

Product Specifications

CAS Number

[1803193-57-8]

Product Name Alternative

R6238-d4

UNSPSC

12352005

Hazard Statement

H302

Target

Adrenergic Receptor; Dopamine Receptor; STAT

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; JAK/STAT Signaling; Neuronal Signaling; Stem Cell/Wnt

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology; Neurological Disease

Purity

99.2

Solubility

10 mM in DMSO

Smiles

O=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=C([2H])C([2H])=C(F)C([2H])=C5[2H])CC3

Molecular Formula

C28H25D4F2N3O

Molecular Weight

465.57

Precautions

H302

References & Citations

[1]Ybema CE, et al. Adrenoceptors and dopamine receptors are not involved in the discriminative stimulus effect of the 5-HT1A receptor agonist flesinoxan. Eur J Pharmacol. 1994 Apr 21;256 (2) :141-7.|[2]Cai N, et al. The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression. Am J Transl Res. 2017 Aug 15;9 (8) :3853-3866. eCollection 2017.|[3]Erik A. Nelson, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011 Mar 24; 117 (12) : 3421-3429.